NRX Pharmaceuticals
NRXP
25 hedge funds and large institutions have $9.76M invested in NRX Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 2 closing their positions.
706% more call options, than puts
Call options by funds: $145K | Put options by funds: $18K
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
150% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 4
112% more capital invested
Capital invested by funds: $4.6M → $9.76M (+$5.16M)
14% more funds holding
Funds holding: 22 → 25 (+3)
1.99% more ownership
Funds ownership: 13.36% → 15.35% (+2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$1.07M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$305K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$232K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$159K |
| 5 |
Squarepoint
New York
|
+$106K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$140K |
| 2 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
-$57.6K |
| 3 |
TC
TownSquare Capital
Provo,
Utah
|
-$30.8K |
| 4 |
Morgan Stanley
New York
|
-$18.8K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$401 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TC
26
TownSquare Capital
Provo,
Utah
| – | -$30.8K | -15,041 | Closed |
|
27
Fidelity Investments
Boston,
Massachusetts
| – | -$76 | -37 | Closed |
|
NRXP Hedge Fund Activity: Q2 2025 in Review
25 of the 7,604 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals (NRXP) for Q2 2025, worth a combined $9.76M — up 112% from $4.6M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new NRXP positions and 2 closed out — a net gain of 3 holders — while 10 added to existing stakes and 4 trimmed.
The largest buyer was Anson Funds Management, adding an estimated $1.07M. The largest seller was Marshall Wace, cutting an estimated $140K.
- 25 institutional investors held NRX Pharmaceuticals (NRXP) as of Q2 2025, up from 22 in Q1 2025.
- Funds reported $9.76M of NRX Pharmaceuticals stock for Q2 2025, up 112% quarter-over-quarter.
- 5 funds opened new NRX Pharmaceuticals positions in Q2 2025 and 2 closed out, a net change of +3 holders.
- The largest NRX Pharmaceuticals buyer in Q2 2025 was Anson Funds Management, an estimated $1.07M added.
- The largest NRX Pharmaceuticals seller in Q2 2025 was Marshall Wace, an estimated $140K sold.
Based on aggregated 13F filings for Q2 2025.